Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Spirox

3475 Edison Way, Suite O
Menlo Park, CA 94025

650-487-2203
Website Company Summary Management Team
Management

President/COO/Operations: Bill Beasley (5/31/2015) ; Jack Dombroski (5/31/2061) ; Mike Rosenthal (2/29/2012) ; Neil Hattangadi (5/31/2016)
General Management: Janie Mandrusov (12/31/2015) ; Donald Gonzales (3/31/2013)
Technology: Scott Baron (5/31/2015)
Sales/Marketing: Mark Alley
Customer Service: Lisa Sims
Board

Outside board: (May no longer be on the board) James C. Momtazee (Kohlberg Kravis Roberts & Co. General Partner);  Camille D. Samuels (Venrock Associates Partner) Aftab Kherani (Aisling Capital Partner) Ron Kuppersmith (Texas ENT and Allergy Otolaryngologist - Head and Neck Surgeon) Stacy Enxing Seng (Vascular Therapies Former President)
Advisory board: Tony Natale (Aperture Venture Partners General Partner)
Company

Business description: Spirox is a Menlo Park, CA-based medical device company that is focused on developing minimally invasive technologies that improve the quality of life for patients with nasal obstruction. Spirox, which is developing a novel, minimally invasive system to be used by Ear, Nose and Throat (ENT) physicians and plastic surgeons to treat patients with nasal obstruction, intends to use the funding to complete development, seek US marketing authorization, and initiate product commercialization. Spirox's technology is intended to treat a significant patient population. Each year, more than three million Americans see a physician for symptoms resulting from nasal obstruction and nearly one million procedures are performed to alleviate these symptoms. Standard treatment options include surgery to treat a deviated septum, surgery to reduce the size of the turbinates, and/or surgery to prevent nasal valve collapse. Although treating the nasal valve creates the greatest improvement in airflow for patients suffering from nasal obstruction, the morbidity associated with the current surgical options has resulted in limited use. Spirox aims to remove this barrier with its minimally invasive approach.
Capital

Rounds: 3
Recent Fundings: Mar 2016   Apr 2015
Capital raised: 71.0M
Last Round: 45.0M
Ownership: Private  
VCs include: Venrock Associates Aisling Capital Correlation Ventures;  Aperture Venture Partners;  Western Technology Investment;  HealthQuest Capital
Private equity: KKR

Last Tweets


 

Last Mentions


Overview
Record updated: Feb 2017
Sector: Medical
Rounds: 3
Recent Fundings: Mar 2016   Apr 2015
Capital Raised: 71.0M
Last Round: 45.0M
Ownership: Private